Study on the Structural Effectiveness Of (Semaglutide - GLP-1 Ras) In Weight Loss and Its Effect on Reducing the Risk of Heart Attacks and Strokes

Nawaf.A.Alshamrani[1], Hasan.S.Alshughaybi[1], Sameer.H.Ahmed[2], Haytham.A.Alrahily[3], Samar.S.Almabadi[4], Ahmad.S.Alrizgy[4], Khaled.M.Alharbi[5], Manar.A.Zahrallayali[5], Mohammed.A.Alhamdi[6], Ahmed.O.Alsuhaymi[3]

Pharmacist- Ibn Sina hospital Extended care- Makkah, Ministry of health, Saudi arabia[1]
Pharmacy Technician - Hira General Hospital[2]
Pharmacist assistant - Ibn Sina hospital Extended care- Makkah, Ministry of health, Saudi arabia[3]
Pharmacist- Ibn Sina hospital Extended care- Makkah, Ministry of health, Saudi arabia[4]
Pharmacist assistant - Ibn Sina hospital Extended care- Makkah, Ministry of health, Saudi arabia[5]
Senior pharmacist-Madinah, Health, Yanbu office, Ministry of health-Saudi Arabia[6]

Abstracts

With the increasing facilities of life, advancements in the food technology, stress and depression-oriented job profiles, less sleep and even less physical work has changed the face of human life forever and along with the same has increased the chances of getting sick with all kind of diseases, these diseases were overheard at a point of time but now days every second person is suffering from the same. even in some of the cases children are born with these diseases. Obesity, diabetes, cardio-vascular diseases, etc. are some such diseases that are being treated in routine form and even in some of the cases patient suffering from them do not even realize what they are suffering from, unless and until major losses have occurred. This present study evaluates the respective effectiveness of Semaglutide in the cases of weight loss and in reduction of risk for strokes, the study is in conjugation with the SELECT study done in 41 counties.

Keywords: Semaglutide, Obesity, Heart attack, stroke, weight loss.

1. Introduction

With the increasing facilities of life, advancements in the food technology, stress and depression oriented job profiles, less sleep and even less physical work has changed the face of human life forever and along with the same has increased the chances of getting sick with all kind of diseases, these diseases were overheard at a point of time but now days every second person is

suffering from the same. even in some of the cases children are born with these diseases. Obesity, diabetes, cardio-vascular diseases, etc. are some such diseases that are being treated in routine form and even in some of the cases patient suffering from them do not even realize what they are suffering from, unless and until major losses have occurred.

Nowadays, clinicians around the world are treating expanded numbers of patients with corpulence and cardio-vascular infection around the world scourge of corpulence 1-3 and its relationship to CVD. In spite of the fact that extraordinary advance has been made in high-income nations in changes in cardiovascular dreariness and mortality, 6 this may be stagnating, and the driving cause of passing all-inclusive remains CVD. Weight may be a significant supporter to CVD, but small advance has been made on compelling and strong intercessions to diminish body weight and particularly target the expanded cardiovascular chance related with corpulence. Treatment approaches are changing, in any case, with recharged intrigued in utilizing drugs for weight administration based on progressed understanding of food admissions and vitality adjust direction. Within the nonattendance of set up, successful treatments known to diminish cardiovascular hazard, a crevice exists for cardiologists and other clinicians in tending to overabundance adiposity as a cause of unfavorable cardiovascular results.

Glucagon-like peptide-1 (GLP-1) is a gut hormone released in response to food intake that acts as a satiety signal, stimulates insulin release, inhibits glucagon secretion, and regulates gastric emptying. In expansion, GLP-1 has other impacts that are possibly advantageous from a cardiovascular chance point of view, counting natri-uresis, diuresis, blood weight diminishment, and advancements in aggravation. In line with this, GLP-1 receptor agonists (GLP-1 RAs) have illustrated decrease in hazard of atherosclerotic cardiovascular occasions in a few cardiovascular results trials (CVOTs) in patients with sort 2 diabetes. Within the field of anti-obesity solutions, GLP-1 RAs are the most recent course of drugs to be endorsed for the treatment of obesity. Semaglutide may be a second-generation GLP-1 RA that's in stage 3 clinical trials as an anti-obesity pharmaceutical at a measurement of 2.4 mg once week by week. This article depicts the plan of the Semaglutide Impacts on Cardiovascular Results in Individuals with Overweight or Obesity (SELECT) ponder, centering on its method of reasoning and potential significance. SELECT will be the primary clinical trial planned to investigate the prevalence of a long-acting, week by week GLP-1 RA (semaglutide 2.4 mg) versus fake treatment for lessening of cardiovascular occasions in patients with built up CVD and overweight or weight but without established type 2 diabetes. Both semaglutide and fake treatment are given with way of life suggestions centered on cardiovascular risk reduction. We offer a brief portrayal of the strategies and particular factual contemplations for this trial at the side a comprehensive discourse.

The around the world increment within the predominance of corpulence is contributing to a quick rise in cardiovascular malady and diabetes, with coming about push on health-care frameworks. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, to begin with presented to oversee dysglycaemia, comes about in both weight misfortune and diminishments in major unfavorable cardiovascular occasions (MACE) in patients with diabetes. The Semaglutide Impacts on Heart Illness and Stroke in Patients with Overweight or Weight (SELECT) trial appeared that once-weekly, subcutaneous semaglutide 2Â·4 mg diminished MACE by 20% compared with fake treatment in patients with pre-existing atherosclerotic cardio-vascular

infection and overweight, but who did not have diabetes. The increase in corpulence within the common populace has too been related with a rise in heart disappointment predominance. An expansive extent of patients with heart disappointment and weight have heart disappointment with protected launch division, which is likely to be causally related to the pathophysiological results of weight.

Heart failure with decreased discharge division and heart disappointment with protected launch division share numerous clinical highlights, but their cause and reaction to treatment are diverse, with benefits of conventional medicines for heart disappointment with diminished launch division being less clear in patients with heart disappointment with protected discharge division. In spite of the fact that SGLT2 inhibitors have been appeared to move forward heart disappointment results in both heart disappointment with protected discharge division and heart disappointment with diminished launch division in patients with or without diabetes, there remains a impressive neglected clinical require, particularly in patients with overweight or corpulence. Within the STEP-HFpEF trials, semaglutide 2Â·4 mg week after week diminished heart disappointment side effects and made strides work out work in patients with obesity-related heart disappointment with protected discharge division with and without diabetes, by focusing on metabolic drivers associated with corpulence instead of myocardial stacking or neurohumoral arbiters. Be that as it may, the measure of those clinical trials blocked the agents from drawing conclusions approximately the impact of semaglutide on clinical heart disappointment occasions, MACE, or mortality. The impact of semaglutide on heart disappointment results and MACE in patients with heart disappointment with diminished launch division has not been studied in devoted clinical trials, and this is often of clinical significance since there has been concern that a few GLP-1 receptor agonists may be incapable or possibly hurtful in this setting. In SELECT, 4286 of the selected patients had a history of investigator-defined heart disappointment, categorised to be heart disappointment with protected discharge division, heart disappointment with diminished launch division, or unclassified. We report a prespecified examination of the impact of once-weekly subcutaneous semaglutide 2Â·4 mg on ischaemic and heart disappointment cardiovascular results. In these patients, we inquired the taking after questions.

2. Research Process:

The study was conducted in the randomly selected hospitals and the reference is taken from the previous study by the name of SELECT which was conducted in 41 countries. In this study the evaluation was made to find that if semaglutide 2·4 mg is given once a week can exceed the effect of placebo in reducing the risk of MACE in patients with established cardiovascular disease and overweight or obesity, without a history of diabetes. Details of study design, population, and primary outcome have been reported previously.

Adults of age 45 were targeted for the study, with a BMI of 27 kg/mÂ² or more noteworthy and set up cardiovascular infection were qualified for the think about. Set up cardiovascular illness was characterized as at slightest one of: past myocardial localized necrosis, past ischaemic or haemorrhagic stroke, or symptomatic fringe course infection. Prohibition criteria included past myocardial dead tissue, stroke, hospitalization for unsteady angina pectoris, or a temporal

ischaemic assault inside 60 days of screening; glycated hemoglobin (HbA1c) of 6Â·5% (48 mmol/mol) or more prominent; history of any frame of diabetes; Modern York Heart Affiliation (NYHA) course IV heart disappointment; nearness of end-stage kidney illness; or require for inveterate or discontinuous dialysis. Sex was examiner detailed as being either male or female. The show, prespecified examination investigated the impacts of semaglutide versus fake treatment in patients who were selected with an investigator-defined history of heart disappointment and stratified by heart disappointment subtype. Patients were classified as having heart disappointment with protected launch division, heart disappointment with diminished launch division, or unclassified heart disappointment at the time of enrolment. For incorporation in SELECT, agents were inquired to supply an NYHA lesson, and in spite of the fact that echocardiographic examinations were not required for inclusion, investigators were inquired to supply key parameters from the foremost later echocardiogram (ECG; inside 18 months), counting cleared out ventricular discharge division (LVEF). After the primary 1783 patients were selected to the think about, examiners were inquired to characterize LVEF into three categories: less than 40%, 40â€ " 49%, and 50% and more prominent. The think about is enrolled with ClinicalTrials.gov, NCT03574597. Randomisation and veiling Patients were haphazardly relegated (1:1) with a piece estimate of four utilizing an intuitively web reaction framework in a double-blind way to raising dosages of once-weekly subcutaneous semaglutide over 16 weeks to a target measurement of 2Â·4 mg, or placebo. The trial item (the write gadget) containing the semaglutide and the fake treatment was outwardly indistinguishable and was pressed in a way that kept up concealing. Examiners were permitted to decrease the ponder item on the off chance that there were tolerability issues. It was prescribed that patients were treated agreeing to the evidence-based standard of care. The convention and pattern characteristics have been distributed already.

3. Statistical Results:

	Patients with heart failure	Patients without heart failure	Patients with heart failure with preserved ejection fraction
Age, years	(8·7)	(8·9)	(8·7)
Sex			
Male	(73·4%)	(72·0%)	(68·9%)
Female	(26·6%)	(28·0%)	(31·1%)
Race*			
White	(89·6%)	(82·2%)	(91·2%)
Asian	(4·8%)	(9·3%)	(4·7%)
Black or African American	(3·2%)	(4·0%)	(2·2%)
Other†	(2·1%)	(3·3%)	(1·9%)
Ethnicity*			
Hispanic or Latino	(9·5%)	(10·6%)	(8·6%)
Region			
North America	(15·4%)	(28·1%)	(11·4%)
South America	(7·8%)	(6·1%)	(7·3%)
Europe	(29·3%)	(40·8%)	(23·8%)
Africa	(2·5%)	(5·5%)	(1·1%)
Asia	(7·4%)	(14·2%)	(6·4%)

Other	(37·5%)	(5·3%)	(50·0%)
Cardiovascular inclusion criteria			
Myocardial infarction only	(71·0%)	(68·4%)	(70·3%)
Stroke only	(13·5%)	(19·7%)	(15·7%)
Peripheral artery disease only	(2·6%)	(5·1%)	(3·1%)
≥2 inclusion criteria	(12·9%)	(6·9%)	(10·9%)
New York Heart Association class			
Class I	(32·0%)	..	(33·0%)
Class II	(59·3%)	..	(59·0%)
Class III	(8·5%)	..	(8·0%)
Unknown	(0·3%)	..	(<0·1%)
Smoking status			
Current smoker	(17·7%)	(16·5%)	(17·8%)
Never smoked	(36·0%)	(34·4%)	(40·3%)
Previous smoker	(46·3%)	(49·2%)	(41·9%)
Concomitant medication			
β blockers	(83·4%)	(66·0%)	(82·2%)
Angiotensin-converting-enzyme inhibitors	(49·5%)	(43·6%)	(49·5%)
Angiotensin receptor blockers	(32·9%)	(28·4%)	33·7%)
Thiazides	(8·9%)	(12·4%)	(9·6%)
Loop diuretics	(29·7%)	(7·0%)	(22·6%)
Aldosterone antagonists	(27·3%)	(4·9%)	(17·8%)
Thiazide-like diuretics	(9·5%)	(4·7%)	(12·6%)
Other potassium-sparing diuretics	(0·1%)	(0·3%)	(0·1%)
Angiotensin receptor-neprilysin inhibitor	(5·1%)	(0·4%)	(1·2%)
Bodyweight, kg	(18·7)	(17·3)	(18·5)
BMI, kg/m²			
<30	(24·7%)	(29·8%)	(24·0%)
≥30 to <35	(41·6%)	(42·8%)	(42·7%)
≥35 to <40	(21·3%)	(18·2%)	(20·7%)
≥40 to <45	(8·3%)	(6·2%)	(8·4%)
≥45	(4·1%)	(3·1%)	(4·2%)

Interpretation:

There were anticipated contrasts in drugs at pattern, with the next extent of patients with heart disappointment with diminished discharge division getting circle diuretics and aldosterone enemies compared with those with heart disappointment with protected launch division (table). No patients were accepting an SGLT2 inhibitor at enrolment, but 545 (3Â·1%) of 17 G04 patients begun utilizing an SGLT2 inhibitor amid the ponder. Plasma lipid levels and blood weight were well treated in all bunches at trial section. There were a few minor contrasts between patients with heart disappointment with protected discharge division and patients with heart disappointment with diminished discharge division and those with unclassified heart disappointment (table). For illustration, patients with unclassified heart disappointment were marginally more seasoned and more likely to be female, had higher high-sensitivity C-reactive protein levels, and had lower NYHA lesson. Less patients with unclassified heart disappointment were treated with Î² blockers at pattern compared with patients with heart disappointment with protected discharge division and patients with heart disappointment with diminished discharge division.

4. Discussion:

In previous trials, SGLT2 inhibitors have been shown to result in a significant reduction in cardiovascular death and heart failure events in patients with established heart failure, with and without diabetes, independent of ejection fraction. The improvement in the heart failure composite measure with semaglutide was mainly driven by reduced cardiovascular mortality. Subsequently, caution ought to be connected when translating our discoveries, and the investigations of the components of the heart disappointment composite were not prespecified. At the onset of enlistment into SGLT2 inhibitors were not however portion of standard of care for heart disappointment. Amid the trial, SGLT2 inhibitors were started in as it were a little extent of patients with heart disappointment. Future ponders will be required to investigate the impact of GLP-1 receptor agonists in combination with SGLT2 inhibitors, which show up to have diverse and possibly complementary modes of activity and thus benefits, as proposed within the STEP HFpEF DM trial. Furthermore, combinations with other rising sedate treatments for heart disappointment could be useful. Our think about has both qualities and impediments. The expansive number of patients with heart disappointment and long perception time permitted for vigorous appraisal of the impact of semaglutide in terms of clinical results, unfavorable occasions, and solidness of impacts. All things considered, most members were White men, and future GLP-1 receptor agonist trials ought to be outlined to look at the reaction by ethnicity and sex. In SELECT, the conclusion of heart disappointment and its clinical subtype was made by examiners and based on restorative wellbeing records, without an explicit necessity for echocardiography and heart disappointment biomarker estimation. This approach reflects clinical hone but comes about within the characterization of bunches of patients with a history of past heart disappointment being less exact than in devoted heart disappointment trials. By the by, the investigator-defined heart disappointment gather had considerably higher rates of MACE, heart disappointment composite, and all-cause mortality compared with those without heart disappointment. However, the observed reduction in mortality by semaglutide attenuates our ability to discern a treatment effect on the endpoint of hospitalization or urgent hospital visit for heart failure, in part because mortality acts as a competing risk. We cannot be precise about what is driving the reduction in patients designated as having cardiovascular death, which included sudden cardiovascular death, as well as death from acute myocardial infarction and heart failure. Furthermore, those classified as having a history of heart failure with reduced ejection fraction had nearly twice the rate of these events compared with those classified as having heart failure with preserved ejection fraction.

WORKS CITED

Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2021; 143: e984–1010.

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989–1002.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–44.

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023; 389: 2221–32.

Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434–50.
Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA 2023; 329: 827–38.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451–61.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995–2008.
Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819–29.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023; 389: 1069–84.
Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024; 390: 1394–407.
Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017; 19: 69–77.
Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016; 316: 500–08.
Sharma A, Ambrosy AP, DeVore AD, et al. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Fail 2018; 5: 1035–43.
Fudim M, White J, Pagidipati NJ, et al. Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial. Circulation 2019; 140: 1613–22.
Khan MS, Fonarow GC, McGuire DK, et al. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation 2020; 142: 1205–18.
Lingvay I, Brown-Frandsen K, Colhoun HM, et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring) 2023; 31: 111–22.
American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2024. Diabetes Care 2024; 47 (suppl 1): S20–42.
Amdahl MB, Sundaram V, Reddy YNV. Obesity in heart failure with reduced ejection fraction: time to address the elephant in the room. Cardiol Clin 2023; 41: 537–44.
Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab 2016; 24: 15–30.
Morgan Stanley. Could obesity drugs take a bite out of the food industry? Sept 5, 2023. https://www.morganstanley.com/ideas/obesity-drugs-food-industry (accessed June 20, 2024).
Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024; 149: 450–62.